Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation
This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta275
1.1 Apixaban is recommended as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with nonvalvular atrial fibrillation with 1 or more risk factors such as:
prior stroke or transient ischaemic attack
age 75 years or older
symptomatic heart failure.
1.2 The decision about whether to start treatment with apixaban should be made after an informed discussion between the clinician and the person about the risks and benefits of apixaban compared with warfarin, dabigatran etexilate and rivaroxaban. For people who are taking warfarin, the potential risks and benefits of switching to apixaban should be considered in light of their level of international normalised ratio (INR) control.